Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT-01: SCRI-CAR19v3 in Treatment-Refractory Systemic Lupus Erythematosus
NCT06465147Phase 1Recruiting
- Sponsor
- Seattle Children's
- Start
- Dec 2024
- Primary completion
- Oct 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SCRI-CAR19v3 in systemic lupus erythematosus (SLE), sponsored by Seattle Children's. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days and Rate of SCRI-CAR19v3 Manufacturing Success at 28 days. Started Dec 2024; status: recruiting.
02
Drugs
SCRI-CAR19v3
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06465147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465147.